{"id":"NCT01886690","sponsor":"Allergan","briefTitle":"A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-20","primaryCompletion":"2014-08-18","completion":"2014-08-18","firstPosted":"2013-06-26","resultsPosted":"2015-10-05","lastUpdate":"2019-04-16"},"enrollment":148,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bilateral LASIK Surgery"],"interventions":[{"type":"DRUG","name":"carboxymethylcellulose sodium based new eye drop formulation","otherNames":[]},{"type":"DRUG","name":"carboxymethylcellulose sodium based eye drops","otherNames":["REFRESH PLUS®"]}],"arms":[{"label":"New Eye Drop Formulation","type":"EXPERIMENTAL"},{"label":"REFRESH PLUS®","type":"ACTIVE_COMPARATOR"}],"summary":"This study will compare the safety and efficacy of a new eye drop formulation with REFRESH PLUS® in participants following LASIK surgery.","primaryOutcome":{"measure":"Ocular Surface Disease Index© (OSDI) Score Using a 5-Point Scale","timeFrame":"Day 90","effectByArm":[{"arm":"New Eye Drop Formulation","deltaMin":6.99,"sd":8.511},{"arm":"REFRESH PLUS®","deltaMin":6.63,"sd":7.071}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":5},"locations":{"siteCount":2,"countries":["Australia","Canada"]},"refs":{"pmids":["29765198"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":["Headache","Blepharitis","Nasopharyngitis"]}}